Bristol-Myers Squibb (BMY) Holdings Trimmed by Ontario Teachers Pension Plan Board

Ontario Teachers Pension Plan Board lessened its holdings in Bristol-Myers Squibb (NYSE:BMY) by 82.8% in the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 10,648 shares of the biopharmaceutical company’s stock after selling 51,100 shares during the quarter. Ontario Teachers Pension Plan Board’s holdings in Bristol-Myers Squibb were worth $653,000 as of its most recent SEC filing.

Several other institutional investors have also made changes to their positions in BMY. American International Group Inc. lifted its position in Bristol-Myers Squibb by 5.1% during the fourth quarter. American International Group Inc. now owns 531,907 shares of the biopharmaceutical company’s stock worth $32,595,000 after purchasing an additional 25,634 shares during the period. D L Carlson Investment Group Inc. raised its stake in Bristol-Myers Squibb by 9.4% during the fourth quarter. D L Carlson Investment Group Inc. now owns 59,039 shares of the biopharmaceutical company’s stock worth $3,618,000 after acquiring an additional 5,087 shares in the last quarter. Arrowstreet Capital Limited Partnership raised its stake in Bristol-Myers Squibb by 27.9% during the fourth quarter. Arrowstreet Capital Limited Partnership now owns 6,494,220 shares of the biopharmaceutical company’s stock worth $397,966,000 after acquiring an additional 1,417,638 shares in the last quarter. Centaurus Financial Inc. acquired a new position in Bristol-Myers Squibb during the fourth quarter worth about $299,000. Finally, Employees Retirement System of Texas raised its stake in Bristol-Myers Squibb by 1.3% during the fourth quarter. Employees Retirement System of Texas now owns 554,900 shares of the biopharmaceutical company’s stock worth $34,004,000 after acquiring an additional 7,000 shares in the last quarter. 71.51% of the stock is owned by institutional investors.

How to Become a New Pot Stock Millionaire

BMY has been the subject of several research analyst reports. Vetr downgraded Bristol-Myers Squibb from a “buy” rating to a “hold” rating and set a $59.70 target price for the company. in a research note on Friday, December 22nd. Zacks Investment Research downgraded Bristol-Myers Squibb from a “hold” rating to a “sell” rating in a research note on Tuesday, January 9th. BMO Capital Markets reissued a “sell” rating and set a $52.00 target price on shares of Bristol-Myers Squibb in a research note on Monday, January 22nd. Credit Suisse Group set a $62.00 target price on Bristol-Myers Squibb and gave the stock a “hold” rating in a research note on Monday, January 22nd. Finally, Leerink Swann boosted their target price on Bristol-Myers Squibb from $71.00 to $76.00 and gave the stock a “positive” rating in a research note on Tuesday, February 6th. Three analysts have rated the stock with a sell rating, eleven have given a hold rating and ten have assigned a buy rating to the stock. The company has a consensus rating of “Hold” and a consensus price target of $66.45.

Shares of Bristol-Myers Squibb stock traded down $4.57 on Monday, hitting $54.08. The stock had a trading volume of 34,834,491 shares, compared to its average volume of 8,101,045. Bristol-Myers Squibb has a twelve month low of $51.56 and a twelve month high of $70.05. The company has a debt-to-equity ratio of 0.59, a current ratio of 1.55 and a quick ratio of 1.43. The company has a market capitalization of $95,750.99, a P/E ratio of 17.97, a P/E/G ratio of 1.52 and a beta of 0.96.

Bristol-Myers Squibb (NYSE:BMY) last released its earnings results on Monday, February 5th. The biopharmaceutical company reported $0.68 earnings per share for the quarter, beating analysts’ consensus estimates of $0.67 by $0.01. The business had revenue of $5.45 billion during the quarter, compared to the consensus estimate of $5.35 billion. Bristol-Myers Squibb had a net margin of 4.85% and a return on equity of 35.43%. The company’s revenue for the quarter was up 3.9% compared to the same quarter last year. During the same quarter in the prior year, the firm posted $0.63 EPS. equities analysts anticipate that Bristol-Myers Squibb will post 3.22 EPS for the current year.

The company also recently announced a quarterly dividend, which will be paid on Tuesday, May 1st. Shareholders of record on Friday, April 6th will be given a dividend of $0.40 per share. This represents a $1.60 dividend on an annualized basis and a yield of 2.96%. The ex-dividend date of this dividend is Thursday, April 5th. Bristol-Myers Squibb’s dividend payout ratio is presently 53.16%.

ILLEGAL ACTIVITY NOTICE: This piece of content was posted by Week Herald and is owned by of Week Herald. If you are accessing this piece of content on another publication, it was illegally stolen and republished in violation of United States & international trademark & copyright law. The correct version of this piece of content can be viewed at https://weekherald.com/2018/04/16/ontario-teachers-pension-plan-board-decreases-position-in-bristol-myers-squibb-co-bmy.html.

Bristol-Myers Squibb Company Profile

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, and distributes biopharmaceutical products worldwide. The company offers drugs in the various therapeutic classes, such as oncology; cardiovascular; immunoscience; and virology, including human immunodeficiency virus (HIV) infection.

Institutional Ownership by Quarter for Bristol-Myers Squibb (NYSE:BMY)

Receive News & Ratings for Bristol-Myers Squibb Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bristol-Myers Squibb and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply